(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Virtual. About Innate Pharma. Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunothera ...

Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...

AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Scientists from the University of Sheffield and AstraZeneca have created an AI approach that could make designing proteins ...

Demand is rising for AI-powered robots that can clean offices or roll around moving items from one part of a building to ...

JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.